Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis

BMC Musculoskeletal Disorders - Tập 21 Số 1 - 2020
Zhong-yu Gao1, Tao Zhang1, Hui Zhang1, Cheng-gang Pang2, Wenxue Jiang1
1Department of Orthopedic Surgery, Tianjin First Central Hospital, 24 Fukang Rd, Nankai District, Tianjin, 300192, China
2Graduate School, Tianjin Medical University, Tianjin, 300070, China

Tóm tắt

Abstract Background To guide the selection of treatments for spinal metastases, the expected survival time is one of the most important determinants. Few scoring systems are fully applicable for spinal metastasis secondary to prostate cancer (PCa). This study aimed to identify the independent factors to predict the overall survival (OS) of patients with spinal metastases from PCa. Methods The PubMed, Embase and CENTRAL were retrieved by two reviewers independently, to identify studies analyzed the prognostic effect of different factors in spinal metastasis from PCa. A systematic review and quantitative meta-analysis was conducted with hazard ratio (HR) and 95% confidence interval (95%CI) as the effect size. Results A total of 12 retrospective cohort studies (1566 patients) were eligible for qualitative synthesis and 10 for quantitative meta-analyses. The OS was significantly influenced by performance status, visceral metastasis, ambulatory status and time from PCa diagnosis in more than half of the available studies. The meta-analyses demonstrated that OS was significantly influenced by visceral metastasis (HR = 2.24, 95%CI:1.53–3.27, p < 0.001), pre-treatment ambulatory status (HR = 2.64, 95%CI:1.82–3.83, p < 0.001), KPS (HR = 4.45, 95%CI:2.01–9.85, p < 0.001), ECOG (HR = 2.96, 95%CI:2.02–4.35, p < 0.001), extraspinal bone metastasis (HR = 2.04, 95%CI:1.13–3.68, p = 0.018), time developing motor deficit (HR = 1.57, 95%CI:1.30–1.88, p < 0.001) and time from PCa diagnosis (HR = 1.37, 95%CI:1.17–1.59, p < 0.001). Conclusions Visceral metastasis, ambulatory status, extraspinal bone metastasis, performance status, time developing motor deficit and time interval from primary tumor diagnosis were significantly associated with the OS for spinal metastasis from PCa. When selecting the treatment modality, clinicians should fully consider the patients’ systematic status based on all potential prognostic factors. Level of evidence I Meta-analysis.

Từ khóa


Tài liệu tham khảo

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578–83.

Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res. 2011;17(12):3924–32.

Gokaslan ZL. Spine surgery for cancer. Curr Opin Oncol. 1996;8:178–81.

Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1–18.

Higano CS. To treat or not to treat, that is the question: the role of bonetargeted therapy in metastatic prostate cancer. J Clin Oncol. 2014;32:1107–11.

Zhang D, Yin H, Wu Z, Yang X, Liu T, Xiao J. Surgery and survival outcomes of 22 patients with epidural spinal cord compression caused by thyroid tumor spinal metastases. Eur Spine J. 2013;22:569–76.

Sciubba DM, Petteys RJ, Dekutoski MB, Fisher CG, Fehlings MG, Ondra SL, et al. Diagnosis and management of metastatic spine disease. A review. J Neurosurg Spine. 2010;13(1):94–108.

Gabriel K, Schiff D. Metastatic spinal cord compression by solid tumors. Semin Neurol. 2004;24(4):375–83.

Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine. 2005;30:2186–91.

Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine (Phila Pa 1976). 2001;26(3):298–306.

van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW, Dutch bone metastasis study group. Prediction of survival in patients with metastases in the spinal column Results based on a randomized trial of radiotherapy. Cancer. 2005;103:320–8.

Bauer HC, Wedin R. Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients. Acta Orthop Scand. 1995;66:143–6.

Crnalic S, Löfvenberg R, Bergh A, Widmark A, Hildingsson C. Predicting survival for surgery of metastatic spinal cord compression in prostate cancer: a new score. Spine (Phila Pa 1976). 2012;37(26):2168–76.

Ju DG, Zadnik PL, Groves ML, Hwang L, Kaloostian PE, Wolinksy JP, et al. Factors associated with improved outcomes following decompressive surgery for prostate cancer metastatic to the spine. Neurosurgery. 2013;73(4):657–66.

Meng T, Chen R, Zhong N, Fan T, Li B, Yin H, et al. Factors associated with improved survival following surgical treatment for metastatic prostate cancer in the spine: retrospective analysis of 29 patients in a single center. World J Surg Oncol. 2016;14(1):200.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

Wells GA, Shea B, O’Connell D. Newcastle-Ottawa quality assessment scale cohort studies. 2012. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ. 2003;327:557–60.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

Huddart RA, Rajan B, Law M, Meyer L, Dearnaley DP. Spinal cord compression in prostate cancer treatment outcome prognostic factors. Radiother Oncol. 1997;44(3):229–36.

Williams BJ, Fox BD, Sciubba DM, Suki D, Tu SM, Kuban D, et al. Surgical management of prostate cancer metastatic to the spine. J Neurosurg Spine. 2009;10(5):414–22.

Rades D, Douglas S, Veninga T, Bajrovic A, Stalpers LJ, Hoskin PJ, et al. A survival score for patients with metastatic spinal cord compression from prostate cancer. Strahlenther Onkol. 2012;188(9):802–6.

Crnalic S, Hildingsson C, Wikström P, Bergh A, Löfvenberg R, Widmark A. Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer. Acta Orthop. 2012;83(1):80–6.

Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S. Predictors of survival inpatients with prostate cancer and spinal metastasis. Presented at the 2009 joint spine section meeting. Clinical article. J Neurosurg Spine. 2010;13(6):789–94.

Zakaria HM, Massie L, Basheer A, Elibe E, Boyce-Fappiano D, Shultz L, et al. Application of Morphometrics as a predictor for survival in patients with prostate Cancer metastasis to the spine. World Neurosurg. 2018;114:e913–9.

Rades D, Conde-Moreno AJ, Cacicedo J, Segedin B, Veninga T, Schild SE. Metastatic spinal cord compression a survival score particularly developed for elderly prostate Cancer patients. Anticancer Res. 2015;35(11):6189–92.

Lehrmann-Lerche CS, Thomsen FB, Røder MA, Suppli MH, Brasso K, Berg KD. Prognostic implication of gait function following treatment for spinal cord compression in men diagnosed with prostate cancer. Scand J Urol. 2019;53(4):222–8.

Weber A, Bartscht T, Karstens JH, Schild SE, Rades D. Survival in patients with metastatic spinal cord compression from prostate cancer is associated with the number of extra-spinal organs involved. Anticancer Res. 2013;33(10):4505–7.

Enkaoua EA, Doursounian L, Chatellier G, Mabesoone F, Aimard T, Saillant G. Vertebral metastases: a critical appreciation of the preoperative prognostic tokuhashi score in a series of 71 cases. Spine (Phila Pa 1976). 1997;22(19):2293–8.

Bartels RH, Feuth T, van der Maazen R, Verbeek AL, Kappelle AC, André Grotenhuis J, et al. Development of a model with which to predict the life expectancy of patients with spinal epidural metastasis. Cancer. 2007;110(9):2042–9.

Sioutos PJ, Arbit E, Meshulam CF, Galicich JH. Spinal metastases from solid tumors. Analysis of factors affecting survival. Cancer. 1995;76:1453–9.

Rades D, Fehlauer F, Schulte R, Veninga T, Stalpers LJ, Basic H, et al. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol. 2006;24(21):3388–93.

Laufer I, Rubin DG, Lis E, Cox BW, Stubblefield MD, Yamada Y, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist. 2013;18:744–51.

Thông tin
Thông tin xuất bản

BMC Musculoskeletal Disorders

Tập 21 Số 1

Thông tin tác giả